Zoetis Faces Securities Fraud Investigation After CEO's Optimistic Guidance Preceded Guidance Cut

What happened

Zoetis CEO told investors on early 2026 that the macro environment would "gradually improve" and guided for 3%-5% organic revenue growth for FY 2026. Just weeks later, the company slashed its full-year revenue guidance, causing shares to plummet 21.5% on May 7, 2026. This dramatic reversal has prompted a securities fraud investigation by Levi & Korsinsky, which alleges that management's statements were misleading. The investigation adds a legal overhang to Zoetis's existing challenges, including U.S. Librela safety concerns and sluggish OA mAb adoption. The stock now trades near $125, roughly 28% below early-2025 levels, with the investigation threatening to further erode investor confidence.

Implication

In the near term, the investigation will likely depress sentiment and keep the stock under pressure, potentially testing the $110 attractive entry identified in our base case. If the investigation uncovers systemic disclosure issues, it could force management to allocate significant time and resources to legal defense, delaying the OA mAb recovery and strategic initiatives. The broader fundamental thesis—mid-single-digit growth, competitive pressure, and OA overhang—remains intact, but the investigation adds uncertainty that may not resolve for 12-18 months. The re-assessment window should be pushed out to 12-18 months, with a lower conviction until the legal outcome is known. For current holders, the risk-reward is unfavorable; a wait-and-see approach is prudent, with a lower entry point around $100 to account for the additional risk.

Thesis delta

The securities fraud investigation introduces a new layer of uncertainty that was not present in our previous WAIT thesis. While we already saw limited near-term upside from current 21x P/E and mid-single-digit growth, the investigation raises the risk of prolonged legal distraction and potential penalties, which could delay the OA mAb stabilization we flagged as a key catalyst. Consequently, we lower our conviction and extend the re-assessment window to 12-18 months, with a more cautious stance until clarity emerges.